Eli Lilly (LLY) just put fresh clinical data on the table, showing that combining Taltz and Zepbound shifted more psoriasis and metabolic biomarkers than Taltz alone for patients with psoriasis and obesity.
Eli Lilly shares trade at US$1,166.51 after a small 1 day decline of 1.36%, while a 30 day share price return of 4.55% and a year to date gain of 7.97% point to steady, if moderating, momentum ahead of upcoming earnings and heavy news flow on obesity, cardiometabolic and immunology therapies. Over a longer horizon, a 1 year total shareholder return of 44.50% and roughly 96% over 3 years, climbing to just over 4x over 5 years, indicates that investors have been rewarding the expanding GLP 1 and dermatology pipeline, with fresh psoriasis and obesity data fitting into that broader story rather than radically changing sentiment.
See how Eli Lilly fits into the broader cardiometabolic and obesity treatment landscape by comparing it with a curated group of 33 healthcare AI stocks.
The recent pullback came after a long run driven by cardiometabolic and dermatology headlines, not a single data point. Is Eli Lilly’s current price now mostly a story about the pipeline, or about sentiment crowding into a scarce asset?
Most Popular Narrative: 21% Undervalued
Compared with Eli Lilly’s last close at $1,166.51, the most followed valuation story pegs fair value near $1,477, which implies a sizable gap that investors are still debating.
The model uses four inputs to arrive at the fair value: a growth rate that has been adjusted to 18% to reflect reality rather than the overly conservative 12.71% default; a future PE ratio of 30 times earnings in 2031, down from today's 39 times, which accounts for the natural compression in valuation multiples as a company matures and grows larger; a discount rate of 7.5%, slightly above the default of 6.98%, to honestly account for the pipeline risks that still exist; and earnings by 2031 of approximately $48 to $50 billion, above the model's $41.5 billion, because at 18% growth and stable margins, that is where the numbers actually land.
See why 77 investors see Eli Lilly as 21% undervalued.
This narrative, according to AHaron, also leans on Eli Lilly trading about 30.1% below an internal fair value estimate and below a future cash flow value of $1,668.16 from the SWS DCF model, which helps explain why some holders frame recent volatility more as noise than thesis change.
Result: Fair Value of $1,477.03 (UNDERVALUED)
Still, the thesis around Eli Lilly can unravel quickly if pricing pressure on GLP 1s intensifies, or if any late stage trial throws up an unexpected safety issue.
Find out about the key risks to this Eli Lilly narrative.
Next Steps
The mix of enthusiasm and caution around Eli Lilly only matters if you test it against your own framework, so move quickly, review both the bright spots and the weak links, and weigh the 3 key rewards and 1 important warning sign.
Looking for more Eli Lilly sized investment ideas?
Do not stop with Eli Lilly. Use the Simply Wall Street Screener to quickly surface fresh opportunities that fit your risk appetite and return goals before others move first.
- Target potential mispricing by scanning for companies flagged as a 32 high quality undervalued stocks that might suit a value focused approach.
- Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (25 results) so you can focus on businesses with stronger financial footing.
- Spot overlooked potential by checking a 20 high quality undiscovered gems before they appear on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com